Blog

Societies

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Photo taken from Grainne O’Kane/X

Jun 5, 2024, 13:27

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:

“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.

Important to remember most on PDAC trials less than 70 years.
Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
Need to identify who can benefit and discuss with patients.”

GIANT trial

Source: Grainne O’Kane/X

5‐Fluorouracil ASCO ASCO24 cancer Gemcitabine plus nab-Paclitaxel (GnP) Grainne O’Kane OncoDaily Oncology Overall survival (OS) pancreatic ductal adenocarcinoma (PDAC)

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage